{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:30:31Z","timestamp":1788283831263,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40265-024-02068-7","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:02:29Z","timestamp":1718892149000},"page":"825-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Analysis of Cerebrospinal Fluid, Plasma \u03b2-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801\/Valiltramiprosate in APOE4 Carriers with Early Alzheimer\u2019s Disease Using Quantitative Systems Pharmacology Model"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-6231","authenticated-orcid":false,"given":"John A.","family":"Hey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Abushakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean F.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kesslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"11","key":"2068_CR1","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","volume":"16","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer\u2019s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2020;16(11):1553\u201360. https:\/\/doi.org\/10.1016\/j.jalz.2019.09.075.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2068_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95. https:\/\/doi.org\/10.1186\/s13195-020-00663-w.","journal-title":"Alzheimers Res Ther."},{"key":"2068_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126355","author":"M Tolar","year":"2021","unstructured":"Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22126355.","journal-title":"Int J Mol Sci"},{"key":"2068_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052727","author":"M Tolar","year":"2024","unstructured":"Tolar M, Hey JA, Power A, Abushakra S. The single toxin origin of Alzheimer\u2019s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25052727.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2068_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","volume":"57","author":"JA Hey","year":"2018","unstructured":"Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet. 2018;57(3):315\u201333. https:\/\/doi.org\/10.1007\/s40262-017-0608-3.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2068_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","volume":"31","author":"P Kocis","year":"2017","unstructured":"Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, et al. Elucidating the abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer\u2019s disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs. 2017;31(6):495\u2013509. https:\/\/doi.org\/10.1007\/s40263-017-0434-z.","journal-title":"CNS Drugs"},{"issue":"9","key":"2068_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","volume":"32","author":"JA Hey","year":"2018","unstructured":"Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnalek M, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs. 2018;32(9):849\u201361. https:\/\/doi.org\/10.1007\/s40263-018-0554-0.","journal-title":"CNS Drugs"},{"issue":"3","key":"2068_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jalz.2006.03.009","volume":"2","author":"PS Aisen","year":"2006","unstructured":"Aisen PS. Development of a disease-modifying treatment for Alzheimer\u2019s disease: Alzhemed. Alzheimers Dement. 2006;2(3):153\u20134. https:\/\/doi.org\/10.1016\/j.jalz.2006.03.009.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2068_CR9","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","volume":"67","author":"PS Aisen","year":"2006","unstructured":"Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67(10):1757\u201363. https:\/\/doi.org\/10.1212\/01.wnl.0000244346.08950.64.","journal-title":"Neurology"},{"issue":"4","key":"2068_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/156720507781788882","volume":"4","author":"PS Aisen","year":"2007","unstructured":"Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, et al. Alzhemed: a potential treatment for Alzheimer\u2019s disease. Curr Alzheimer Res. 2007;4(4):473\u20138. https:\/\/doi.org\/10.2174\/156720507781788882.","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"2068_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28(4):537\u201347. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2006.02.015.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"2068_CR12","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/jnr.22393","volume":"88","author":"T Ariga","year":"2010","unstructured":"Ariga T, Miyatake T, Yu RK. Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer\u2019s disease and related disorders: amyloidogenesis and therapeutic strategies\u2013a review. J Neurosci Res. 2010;88(11):2303\u201315. https:\/\/doi.org\/10.1002\/jnr.22393.","journal-title":"J Neurosci Res"},{"issue":"9","key":"2068_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.jasms.2010.05.007","volume":"21","author":"E Martineau","year":"2010","unstructured":"Martineau E, de Guzman JM, Rodionova L, Kong X, Mayer PM, Aman AM. Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS. J Am Soc Mass Spectrom. 2010;21(9):1506\u201314. https:\/\/doi.org\/10.1016\/j.jasms.2010.05.007.","journal-title":"J Am Soc Mass Spectrom"},{"issue":"6","key":"2068_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3275\/8585","volume":"24","author":"C Caltagirone","year":"2012","unstructured":"Caltagirone C, Ferrannini L, Marchionni N, Nappi G, Scapagnini G, Trabucchi M. The potential protective effect of tramiprosate (homotaurine) against Alzheimer\u2019s disease: a review. Aging Clin Exp Res. 2012;24(6):580\u20137. https:\/\/doi.org\/10.3275\/8585.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"2068_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nchem.2129","volume":"7","author":"LM Young","year":"2015","unstructured":"Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Tu LH, et al. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat Chem. 2015;7(1):73\u201381. https:\/\/doi.org\/10.1038\/nchem.2129.","journal-title":"Nat Chem"},{"issue":"10","key":"2068_CR16","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1021\/acs.jctc.9b00599","volume":"15","author":"C Liang","year":"2019","unstructured":"Liang C, Savinov SN, Fejzo J, Eyles SJ, Chen J. Modulation of amyloid-beta42 conformation by small molecules through nonspecific binding. J Chem Theory Comput. 2019;15(10):5169\u201374. https:\/\/doi.org\/10.1021\/acs.jctc.9b00599.","journal-title":"J Chem Theory Comput"},{"key":"2068_CR17","doi-asserted-by":"publisher","DOI":"10.1021\/jacsau.4c00182","author":"SM Marques","year":"2024","unstructured":"Marques SM, Kouba P, Legrand A, Sedlar J, Disson L, Planas-Iglesias J, Sanusi Z, Kunka A, Damborsky J, Pajdla T, Prokop Z, Mazurenko S, Sivic J, Bednar D. CoVAMPnet: comparative Markov state analysis for studying effects of drug candidates on disordered biomolecules. JACS. 2024. https:\/\/doi.org\/10.1021\/jacsau.4c00182.","journal-title":"JACS."},{"issue":"6","key":"2068_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"S Gauthier","year":"2009","unstructured":"Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009;13(6):550\u20137. https:\/\/doi.org\/10.1007\/s12603-009-0106-x.","journal-title":"J Nutr Health Aging"},{"issue":"9","key":"2068_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s12603-009-0217-4","volume":"13","author":"D Saumier","year":"2009","unstructured":"Saumier D, Duong A, Haine D, Garceau D, Sampalis J. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer\u2019s disease: ADAS-cog subscale results from the Alphase Study. J Nutr Health Aging. 2009;13(9):808\u201312. https:\/\/doi.org\/10.1007\/s12603-009-0217-4.","journal-title":"J Nutr Health Aging"},{"issue":"1","key":"2068_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12603-009-0217-4","volume":"7","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, et al. Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2014a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011;7(1):102\u201311. https:\/\/doi.org\/10.1007\/s12603-009-0217-4.","journal-title":"Arch Med Sci"},{"issue":"4","key":"2068_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14283\/jpad.2016.115","volume":"3","author":"S Abushakra","year":"2016","unstructured":"Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, et al. Clinical benefits of tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: the \u201cAPOE4 gene-dose effect.\u201d J Prev Alz Dis. 2016;3(4):219\u201328. https:\/\/doi.org\/10.14283\/jpad.2016.115.","journal-title":"J Prev Alz Dis."},{"issue":"3","key":"2068_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2017.26","volume":"4","author":"S Abushakra","year":"2017","unstructured":"Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, et al. Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential. J Prev Alz Dis. 2017;4(3):149\u201356. https:\/\/doi.org\/10.14283\/jpad.2017.26.","journal-title":"J Prev Alz Dis."},{"issue":"2","key":"2068_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimers Dis."},{"issue":"3","key":"2068_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2068_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2068_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JAD-161201","volume":"58","author":"K Li","year":"2017","unstructured":"Li K, Chan W, Doody RS, Quinn J, Luo S. Alzheimer\u2019s disease neuroimaging I. Prediction of conversion to Alzheimer\u2019s disease with longitudinal measures and time-to-event data. J Alzheimers Dis. 2017;58(2):361\u201371. https:\/\/doi.org\/10.3233\/JAD-161201.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"2068_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11(12): e11170. https:\/\/doi.org\/10.15252\/emmm.201911170.","journal-title":"EMBO Mol Med"},{"issue":"17","key":"2068_CR28","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"issue":"1","key":"2068_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12095","volume":"12","author":"HF Wang","year":"2020","unstructured":"Wang HF, Shen XN, Li JQ, Suckling J, Tan CC, Wang YJ, et al. Clinical and biomarker trajectories in sporadic Alzheimer\u2019s disease: a longitudinal study. Alzheimers Dement (Amst). 2020;12(1): e12095. https:\/\/doi.org\/10.1002\/dad2.12095.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"1","key":"2068_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-020-00636-z","volume":"12","author":"C Hadjichrysanthou","year":"2020","unstructured":"Hadjichrysanthou C, Evans S, Bajaj S, Siakallis LC, McRae-McKee K, de Wolf F, et al. The dynamics of biomarkers across the clinical spectrum of Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):74. https:\/\/doi.org\/10.1186\/s13195-020-00636-z.","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"2068_CR31","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41598-020-78095-7","volume":"11","author":"SA Mofrad","year":"2021","unstructured":"Mofrad SA, Lundervold AJ, Vik A, Lundervold AS. Cognitive and MRI trajectories for prediction of Alzheimer\u2019s disease. Sci Rep. 2021;11(1):2122. https:\/\/doi.org\/10.1038\/s41598-020-78095-7.","journal-title":"Sci Rep"},{"issue":"8","key":"2068_CR32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, et al. Biomarker changes during 20 years preceding Alzheimer\u2019s disease. N Engl J Med. 2024;390(8):712\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2310168.","journal-title":"N Engl J Med"},{"key":"2068_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02931-w","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaque-Alcazar L, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-02931-w.","journal-title":"Nat Med"},{"issue":"1","key":"2068_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/psp4.12478","volume":"9","author":"H Geerts","year":"2020","unstructured":"Geerts H, Wikswo J, van der Graaf PH, Bai JPF, Gaiteri C, Bennett D, et al. Quantitative systems pharmacology for neuroscience drug discovery and development: current status, opportunities, and challenges. CPT Pharmacometr Syst Pharmacol. 2020;9(1):5\u201320. https:\/\/doi.org\/10.1002\/psp4.12478.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"2068_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-024-09905-y","author":"L Cucurull-Sanchez","year":"2024","unstructured":"Cucurull-Sanchez L. An industry perspective on current QSP trends in drug development. J Pharmacokinet Pharmacodyn. 2024. https:\/\/doi.org\/10.1007\/s10928-024-09905-y.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"10","key":"2068_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/psp4.12249","volume":"6","author":"T Karelina","year":"2017","unstructured":"Karelina T, Demin O Jr, Demin O, Duvvuri S, Nicholas T. Studying the progression of amyloid pathology and its therapy using translational longitudinal model of accumulation and distribution of amyloid beta. CPT Pharmacometr Syst Pharmacol. 2017;6(10):676\u201385. https:\/\/doi.org\/10.1002\/psp4.12249.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"1","key":"2068_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-018-0343-5","volume":"10","author":"H Geerts","year":"2018","unstructured":"Geerts H, Spiros A, Roberts P. Impact of amyloid-beta changes on cognitive outcomes in Alzheimer\u2019s disease: analysis of clinical trials using a quantitative systems pharmacology model. Alzheimers Res Ther. 2018;10(1):14. https:\/\/doi.org\/10.1186\/s13195-018-0343-5.","journal-title":"Alzheimers Res Ther."},{"issue":"11","key":"2068_CR38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/psp4.12351","volume":"7","author":"D Clausznitzer","year":"2018","unstructured":"Clausznitzer D, Pichardo-Almarza C, Relo AL, van Bergeijk J, van der Kam E, Laplanche L, et al. Quantitative systems pharmacology model for Alzheimer disease indicates targeting sphingolipid dysregulation as potential treatment option. CPT Pharmacometr Syst Pharmacol. 2018;7(11):759\u201370. https:\/\/doi.org\/10.1002\/psp4.12351.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"2068_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.dadm.2019.01.005","volume":"11","author":"M Bilgel","year":"2019","unstructured":"Bilgel M, Jedynak BM. Predicting time to dementia using a quantitative template of disease progression. Alzheimers Dement (Amst). 2019;11:205\u201315. https:\/\/doi.org\/10.1016\/j.dadm.2019.01.005.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"4","key":"2068_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2174\/1567205017666200302122307","volume":"17","author":"GZ Ferl","year":"2020","unstructured":"Ferl GZ, Fuji RN, Atwal JK, Sun T, Ramanujan S, Quartino AL. Mechanistic modeling of soluble abeta dynamics and target engagement in the brain by anti-abeta mAbs in Alzheimer\u2019s disease. Curr Alzheimer Res. 2020;17(4):393\u2013406. https:\/\/doi.org\/10.2174\/1567205017666200302122307.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"2068_CR41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/psp4.12759","volume":"11","author":"L Lin","year":"2022","unstructured":"Lin L, Hua F, Salinas C, Young C, Bussiere T, Apgar JF, et al. Quantitative systems pharmacology model for Alzheimer\u2019s disease to predict the effect of aducanumab on brain amyloid. CPT Pharmacometr Syst Pharmacol. 2022;11(3):362\u201372. https:\/\/doi.org\/10.1002\/psp4.12759.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"9","key":"2068_CR42","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/alz.12312","volume":"17","author":"K Madrasi","year":"2021","unstructured":"Madrasi K, Das R, Mohmmadabdul H, Lin L, Hyman BT, Lauffenburger DA, et al. Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer\u2019s disease. Alzheimers Dement. 2021;17(9):1487\u201398. https:\/\/doi.org\/10.1002\/alz.12312.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2068_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/molpharm.123.000726","volume":"105","author":"M Markovic","year":"2023","unstructured":"Markovic M, Milosevic J, Wang W, Cao Y. Passive immunotherapies targeting amyloid-beta in Alzheimer\u2019s disease: a quantitative systems pharmacology perspective. Mol Pharmacol. 2023;105(1):1\u201313. https:\/\/doi.org\/10.1124\/molpharm.123.000726.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2068_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/psp4.12876","volume":"12","author":"V Ramakrishnan","year":"2023","unstructured":"Ramakrishnan V, Friedrich C, Witt C, Sheehan R, Pryor M, Atwal JK, et al. Quantitative systems pharmacology model of the amyloid pathway in Alzheimer\u2019s disease: insights into the therapeutic mechanisms of clinical candidates. CPT Pharmacometr Syst Pharmacol. 2023;12(1):62\u201373. https:\/\/doi.org\/10.1002\/psp4.12876.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"4","key":"2068_CR45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/psp4.12912","volume":"12","author":"H Geerts","year":"2023","unstructured":"Geerts H, Walker M, Rose R, Bergeler S, van der Graaf PH, Schuck E, et al. A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer\u2019s disease. CPT Pharmacometr Syst Pharmacol. 2023;12(4):444\u201361. https:\/\/doi.org\/10.1002\/psp4.12912.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"2068_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neurobiolaging.2021.12.015","volume":"113","author":"AN Clement","year":"2022","unstructured":"Clement AN, Ribaldi F, Frisoni GB, Garibotto V, Robert P, Ayache N, et al. SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer\u2019s disease. Neurobiol Aging. 2022;113:73\u201383. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.12.015.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2068_CR47","doi-asserted-by":"publisher","first-page":"fcab091","DOI":"10.1093\/braincomms\/fcab091","volume":"3","author":"C Abi Nader","year":"2021","unstructured":"Abi Nader C, Ayache N, Frisoni GB, Robert P, Lorenzi M. Alzheimer\u2019s Disease Neuroimaging I. Simulating the outcome of amyloid treatments in Alzheimer\u2019s disease from imaging and clinical data. Brain Commun. 2021;3(2):fcab091. https:\/\/doi.org\/10.1093\/braincomms\/fcab091.","journal-title":"Brain Commun."},{"issue":"1","key":"2068_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12117","volume":"6","author":"S Abushakra","year":"2020","unstructured":"Abushakra S, Porsteinsson AP, Sabbagh M, Bracoud L, Schaerer J, Power A, Hey JA, Scott D, Suhy J, Tolar M, Alzheimer\u2019s Disease Neuroimaging Initiative. APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimers Dement (NY). 2020;6(1): e12117. https:\/\/doi.org\/10.1002\/trc2.12117.","journal-title":"Alzheimers Dement (NY)."},{"issue":"1","key":"2068_CR49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1017\/S1355617709990956","volume":"16","author":"ML Balthazar","year":"2010","unstructured":"Balthazar ML, Yasuda CL, Cendes F, Damasceno BP. Learning, retrieval, and recognition are compromised in aMCI and mild AD: are distinct episodic memory processes mediated by the same anatomical structures? J Int Neuropsychol Soc. 2010;16(1):205\u20139. https:\/\/doi.org\/10.1017\/S1355617709990956.","journal-title":"J Int Neuropsychol Soc"},{"key":"2068_CR50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.nicl.2016.12.011","volume":"13","author":"E Moradi","year":"2017","unstructured":"Moradi E, Hallikainen I, Hanninen T, Tohka J. Alzheimer\u2019s Disease Neuroimaging I. Rey\u2019s Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimer\u2019s disease. Neuroimage Clin. 2017;13:415\u201327. https:\/\/doi.org\/10.1016\/j.nicl.2016.12.011.","journal-title":"Neuroimage Clin."},{"issue":"3","key":"2068_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1017\/S1355617720000752","volume":"27","author":"NH Stricker","year":"2021","unstructured":"Stricker NH, Christianson TJ, Lundt ES, Alden EC, Machulda MM, Fields JA, et al. Mayo normative studies: regression-based normative data for the auditory verbal learning test for ages 30\u201391 years and the importance of adjusting for sex. J Int Neuropsychol Soc. 2021;27(3):211\u201326. https:\/\/doi.org\/10.1017\/S1355617720000752.","journal-title":"J Int Neuropsychol Soc"},{"key":"2068_CR52","doi-asserted-by":"publisher","unstructured":"Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins N, et al. Effects of oral ALZ-801\/valiltramiprosate on plasma biomarkers, brain hippocampal volume and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer\u2019s disease. Drugs 2024;84. https:\/\/doi.org\/10.1007\/s40265-024-02067-8.","DOI":"10.1007\/s40265-024-02067-8"},{"issue":"2","key":"2068_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106\u201318. https:\/\/doi.org\/10.1038\/nrneurol.2012.263.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2068_CR54","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11(1):667. https:\/\/doi.org\/10.1038\/s41467-019-14279-8.","journal-title":"Nat Commun"},{"issue":"3","key":"2068_CR55","first-page":"115","volume":"3","author":"AE Roher","year":"2014","unstructured":"Roher AE, Maarouf CL, Kokjohn TA, Whiteside CM, Kalback WM, Serrano G, et al. Neuropathological and biochemical assessments of an Alzheimer\u2019s disease patient treated with the gamma-secretase inhibitor semagacestat. Am J Neurodegener Dis. 2014;3(3):115\u201333.","journal-title":"Am J Neurodegener Dis"},{"issue":"4","key":"2068_CR56","first-page":"158","volume":"5","author":"AE Roher","year":"2016","unstructured":"Roher AE, Maarouf CL, Kokjohn TA, Belden C, Serrano G, Sabbagh MS, et al. Chemical and neuropathological analyses of an Alzheimer\u2019s disease patient treated with solanezumab. Am J Neurodegener Dis. 2016;5(4):158\u201370.","journal-title":"Am J Neurodegener Dis"},{"issue":"4","key":"2068_CR57","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3233\/JAD-170762","volume":"61","author":"TG Beach","year":"2018","unstructured":"Beach TG, Maarouf CL, Intorcia A, Sue LI, Serrano GE, Lu M, et al. Antemortem-postmortem correlation of Florbetapir (18F) PET amyloid imaging with quantitative biochemical measures of abeta42 but not abeta40. J Alzheimers Dis. 2018;61(4):1509\u201316. https:\/\/doi.org\/10.3233\/JAD-170762.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2068_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.23748","volume":"73","author":"TJ Esparza","year":"2013","unstructured":"Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73(1):104\u201319. https:\/\/doi.org\/10.1002\/ana.23748.","journal-title":"Ann Neurol"},{"issue":"2","key":"2068_CR59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid beta oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129(2):183\u2013206. https:\/\/doi.org\/10.1007\/s00401-015-1386-3.","journal-title":"Acta Neuropathol"},{"issue":"Suppl 1","key":"2068_CR60","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.neurobiolaging.2011.09.003","volume":"32","author":"DM Holtzman","year":"2011","unstructured":"Holtzman DM. CSF biomarkers for Alzheimer\u2019s disease: current utility and potential future use. Neurobiol Aging. 2011;32(Suppl 1):S4-9. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.09.003.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"2068_CR61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Ann Neurol. 1995;38(4):643\u20138. https:\/\/doi.org\/10.1002\/ana.410380413.","journal-title":"Ann Neurol"},{"issue":"16","key":"2068_CR62","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289(16):2094\u2013103. https:\/\/doi.org\/10.1001\/jama.289.16.2094.","journal-title":"JAMA"},{"issue":"1","key":"2068_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02068-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T05:01:53Z","timestamp":1722315713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02068-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2068"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02068-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"14 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical study and analyses in this report were supported by Alzheon, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.A.H., S.A., A.P., J.F.S., P.K., and M.T. are employees of Alzheon, Inc. J.Y.Y. serves as a consultant to Alzheon, Inc. All authors own Alzheon stocks and\/or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the assigned ethics committees in the Netherlands and in Czech Republic and by the institutional ethics committees in the Czech Republic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects and their partners, caregivers or legal representatives signed informed consent before participation in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ADNI datasets are publicly available at the website: http\/ADNI.LONI.USC.edu. The ALZ-801 data is proprietary to Alzheon Inc.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"J.A.H. wrote the article in collaboration with J.Y.Y. and J.F.S.; S.A., J.A.H., A.P., P.K., and M.T. designed and conducted the ALZ-801-201 ADBM study and the statistical analysis plan. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}